Circulating and Intracellular miRNAs as Prognostic and Predictive Factors in HER2-Positive Early Breast Cancer Treated with Neoadjuvant Chemotherapy: A Review of the Literature.
Chrystel IscaFrancesco GiottaIlenia MastroliaValentina MascialeFederica CaggiaAngela TossClaudia PiombinoLuca MoscettiMonica BarboliniMichela MaurMassimo DominiciClaudia OmariniPublished in: Cancers (2021)
MicroRNAs (miRNA) are small noncoding RNAs that can act as both oncogene and tumor suppressors. Deregulated miRNA expression has been detected in human cancers, including breast cancer (BC). Considering their important roles in tumorigenesis, miRNAs have been investigated as potential prognostic and diagnostic biomarkers. Neoadjuvant setting is an optimal model to investigate in vivo the mechanism of treatment resistance. In the management of human epidermal growth factor receptor-2 (HER2)-positive early BC, the anti-HER2-targeted therapies have drastically changed the survival outcomes. Despite this, growing drug resistance due to the pressure of therapy is relatively frequent. In the present review, we focused on the main miRNAs involved in HER2-positive BC tumorigenesis and discussed the recent evidence on their predictive and prognostic value.
Keyphrases
- neoadjuvant chemotherapy
- epidermal growth factor receptor
- endothelial cells
- locally advanced
- lymph node
- early breast cancer
- induced pluripotent stem cells
- tyrosine kinase
- rectal cancer
- advanced non small cell lung cancer
- pluripotent stem cells
- sentinel lymph node
- squamous cell carcinoma
- stem cells
- radiation therapy
- early stage
- reactive oxygen species
- cell therapy
- combination therapy
- atomic force microscopy
- mesenchymal stem cells
- risk assessment
- bone marrow
- high speed
- childhood cancer